Patent · US Active

Somatic stem cells

US10143710B2 · kind B2 · utility

0Cited by
17References
10Claims
0Family size

Assignee

Inventor

Key dates

Filing dateAug 12, 2016
Grant dateDec 4, 2018
Priority date
Expiry dateAug 12, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2506/11
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described herein is a method of treating a disorder, the method comprising: administering to a subject in need thereof a composition that contains a population of somatic stem cells that are 0.3-6.0 micrometers in size and CD9+, CD349+, CD133−, CD90−, CD34−, SSEA1+, SSEA4+, CD13+, or Stro1+, wherein the disorder is selected from the group consisting of a neurodegenerative disease, nervous system disorder, cancer, metabolic disorder, autoimmune disorder, inflammatory disorder, heart or circulatory disorder, blood disorder, muscular dystrophy, gastrointestinal disease, kidney disease, liver disease, lung disease, adrenal disorder, a condition resulting from an injury, a condition associated with aging, and virus infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.